Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients

Addisu Gize Yeshanew; Afework Kassu Gizaw; Biniam Mathewos Tebeje

doi:doi:10.11648/j.iji.20150306.11

| Peer-Reviewed

Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients

Addisu Gize Yeshanew, Afework Kassu Gizaw, Biniam Mathewos Tebeje

Published in International Journal of Immunology (Volume 3, Issue 6)

Received: 9 October 2015 Accepted: 21 October 2015 Published: 26 November 2015

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The range of T cell abnormalities in advanced HIV-1 infection treatment is broad. The defects are both quantitative and qualitative and affect virtually every limb of the immune system. Beyond the precise measurement of naive T cells (CD45RA+CCR7+CD27+CD28+), the differential expression of different molecules on T cell allows the distinction between numerous subsets of resting or antigen-experienced T cells on the treatment. However, in spite of intense investigation, the mechanisms underlying highly active antiretroviral therapy (HAART) –induce immune reconstitution remain to be fully characterized. HAART treatment induced changes in the peripheral distribution of naïve (CD45RA+ CD62L+) and memory CD45RA- CD62L+) cells, CCR5, CXCR4-, CD95- expressing T cells, T-reg cells and on gamma delta (ϒδ) T cells. As a concluding remark prolonged suppression of plasma viral load ( pVL) by HAART improves not only ɑβ T-cell function but also ϒδ T-cell reactivity, and it is strongly recommended that once started the treatment, sever immunocompromized patient should continue the treatment for long time.

Published in	International Journal of Immunology (Volume 3, Issue 6)
DOI	10.11648/j.iji.20150306.11
Page(s)	57-71
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

T-lymphocytes, HIV-1 Infection, Highly Active Antiretroviral Therapy

References

[1]	Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, Huber M, et al. Emergence of Polyfunctional CD8+ T Cells After Prolonged Suppression of Human Immunodeficiency Virus Replication by Antiretroviral Therapy. J Virol. 2008 Apr 1;82(7):3391–404.
[2]	Hatano H, Delwart EL, Norris PJ, Hae Lee, T, Williams JD-, Hunt PW, et al. Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy. Am Soc Microbiol. 2009 Jan;83(1):328–335.
[3]	Amirayan-Chevillard N, Tissot-Dupont H, Capo C, Brunet C, Dignat-George F, Obadia Y, et al. Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients. Clin Exp Immunol. 2000 Apr;120(1):107–112.
[4]	Giovannetti A, Pierdominici M, Mazzetta F, Salemi S, Marziali M, Kuonen D, et al. T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity. Clin Exp Immunol. 2001 Apr;124(1):21–31.
[5]	Yang BH, Floess S, Hagemann S, Deyneko IV, Groebe L, Pezoldt J, Sparwasser T, Lochner M, Huehn J. Development of a unique epigenetic signature during in vivo Th17 differentiation. Nucleic Acids Res.2015 Feb18;43(3):1537-1548.
[6]	Laranjeira P, Pedrosa M, Pedreiro S, Gomes J, Martinho A, Antunes B, et al. Effect of human bone marrow mesenchymal stromal cells on cytokine production by peripheral blood naive, memory and effector T cells. Stem Cell Res Ther. 2015 Jan 5;6(1):3.
[7]	Alberola-Ila J, Hogquist KA, Swan KA, Bevan MJ, Perlmutter RM. Positive and negative selection invokes distinct signaling pathways. J Exp Med.1999 Jul1; 184(1):9-18.
[8]	Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher H-P, Zinkernagel RM, et al. Evidence for a differential avidity model of T cell selection in the thymus. Cell. 1994 Feb 25;76(4):651–663.
[9]	Appay V, van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytom Part J Int Soc Anal Cytol. 2008 Nov;73(11):975–983.
[10]	Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M. Phenotypic Classification of Human CD4+ T Cell Subsets and Their Differentiation. Int Immunol. 2008 Sep 1;20(9):1189–1199.
[11]	Walters SN, Webster KE, Daley S, Grey ST. A role for intrathymic B cells in the generation of natural regulatory T cells. J Immunol. 2014 Jul 1;193(1):170-176.
[12]	Rahemtulla A, Fung-Leung WP, Schilham MW, Kündig TM, Sambhara SR, Narendran A, et al. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature. 1991 Sep 12;353(6340):180–184.
[13]	Poles MA, Barsoum S, Yu W, Yu J, Sun P, Daly J, et al. Human Immunodeficiency Virus Type 1 Induces Persistent Changes in Mucosal and Blood γδ T Cells despite Suppressive Therapy. J Virol. 2003 Oct;77(19):10456–10467.
[14]	Kosub DA, Lehrman G, Milush JM, Zhou D, Chacko E. Gamma/Delta T-Cell Functional Responses Differ after Pathogenic Human Immunodeficiency Virus and Nonpathogenic Simian Immunodeficiency Virus Infections. Am Soc Microbiol. 2008 Feb;82(3):1155–1165.
[15]	Pauza CD, Riedel DJ, Gilliam BL, Redfield RR. Targeting γδ T cells for immunotherapy of HIV disease. Future Virol. 2011 Jan 1;6(1):73–84.
[16]	Martini F, Urso R, Gioia C, De Felici A, Narciso P, Amendola A, et al. γδ T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology. 2000 Aug;100(4):481–486.
[17]	Mavigner M, Cazabat M, Dubois M, L’Faqihi F-E, Requena M, Pasquier C, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest. 2012 Jan 3;122(1):62–69.
[18]	Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis. 2010 Oct 15;202(Suppl 2):S302–308.
[19]	Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008 May 15;46(10):1617–1623.
[20]	Siewe B, Landay A. Key Concepts in the Early Immunology of HIV-1 Infection. Curr Infect Dis Rep. 2012 Feb;14(1):102-109.
[21]	Klatt EC. Pathology of AIDS [Internet]. Florida State University College of Medicine; 2002 [cited 2015 Feb 11]. Available from: http://medbox-stage.uscreen.net/pathology-of-aids/download.pdf
[22]	Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993 Mar;57(1):183–289.
[23]	Lu SS. Pathophysiology of HIV-associated diarrhea. Gastroenterol Clin North Am. 1997;26(2):175–189.
[24]	Rucker J, Doms RW. Chemokine receptors as HIV coreceptors: implications and interactions. AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S241–246.
[25]	Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, Peden KW, et al. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J Immunol Baltim Md 1950. 1998 Sep 15;161(6):3103–3113.
[26]	Pattanapanyasat K, Thakar MR. CD4+ T cell count as a tool to monitor HIV progression & anti-retroviral therapy. Indian J Med Res. 2005 Apr;121(4):539–549.
[27]	Bandera A, Ferrario G, Saresella M, Marventano I, Soria A, Zanini F, et al. CD4+ T Cell Depletion, Immune Activation and Increased Production of Regulatory T Cells in the Thymus of HIV-Infected Individuals. PLoS ONE. 2010 May 24;5(5):e10788.
[28]	Stebbing J, Bower M, Mandalia S, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin Exp Immunol. 2006 Aug;145(2):271–276.
[29]	Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131(2):81–87.
[30]	Li T, Tubiana R, Katlama C, Calvez V, Mohand HA, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. The Lancet. 1998 Jun;351(9117):1682–1686.
[31]	Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25;308(4):387–402.
[32]	Woods ML, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy. AIDS. 1998 Aug;12(12):1491–1494.
[33]	Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996 May 24;272(5265):1167–1170.
[34]	Pattanapanyasat K. Immune status monitoring of HIV/AIDS patients in resource-limited settings: a review with an emphasis on CD4+ T-lymphocyte determination. Asian Pac J Allergy Immunol Launched Allergy Immunol Soc Thail. 2012 Mar;30(1):11–25.
[35]	Peris-Pertusa A, López M, Rallón NI, Restrepo C, Soriano V, Benito JM. Evolution of the functional profile of HIV-specific CD8+ T cells in patients with different progression of HIV infection over 4 years. J Acquir Immune Defic Syndr 1999. 2010 Sep;55(1):29–38.
[36]	Gamberg JC, Bowmer MI, Trahey JC, Campbell CM, Pardoe I, Grant MD. Functional and genetic integrity of the CD8 T-cell repertoire in advanced HIV infection. AIDS Lond Engl. 1999 Oct 22;13(15):2043–2053.
[37]	Kanki PJ, Hamel DJ, Sankalé JL, Hsieh C c, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 1999 Jan;179(1):68–73.
[38]	Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990 Oct 18;347(6294):669–671.
[39]	Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. J Virol. 2005 Oct 27;79(22):14169–14178.
[40]	Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 1997;15:297–322.
[41]	Agnello D, Lankford CSR, Bream J, Morinobu A, Gadina M, O’Shea JJ, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003 May;23(3):147–161.
[42]	Hua W, Jiao Y, Zhang H, Zhang T, Chen D, Zhang Y, et al. Central memory CD4 cells are an early indicator of immune reconstitution in HIV/AIDS patients with anti-retroviral treatment. Immunol Invest. 2012;41(1):1–14.
[43]	Gajewski TF, Lancki DW, Stack R, Fitch FW. “Anergy” of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med. 1994 Feb 1;179(2):481–491.
[44]	King IL, Mohrs M. IL-4-producing CD4+ T cells in reactive lymph nodes during helminth infection are T follicular helper cells. J Exp Med. 2009 May 11;206(5):1001–1007.
[45]	Hunt PW. Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS. 2010 Mar;5(2):189–193.
[46]	Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17–producing helper T cells. Nat Immunol. 2007 Sep;8(9):950–957.
[47]	Appay V, Nixon DF, Donahoe SM, Gillespie GMA, Dong T, King A, et al. HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function. J Exp Med. 2000 Jul 3;192(1):63–76.
[48]	Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity. 1995 Mar;2(3):271–279.
[49]	Onlamoon N, Sukapirom K, Polsrila K, Ammaranond P, Pattanapanyasat K. Alteration of CD8+ T Cell Effector Diversity During HIV-1 Infection with Discordant Normalization in Effective Antiretroviral Therapy. Int Clin Cytom Soc. 2011 Sep;35–42.
[50]	Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002 May 2;417(6884):95–98.
[51]	Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997 Nov 21;278(5342):1447–1450.
[52]	Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994 Sep;68(9):6103–6110.
[53]	Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo GCDAMDOPPDDPNET. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci. 2005;102(20):7239–7244.
[54]	Akinsiku OT, Bansal A, Sabbaj S, Heath SL, Goepfert PA. Interleukin-2 Production by Polyfunctional HIV-1-Specific CD8 T Cells Is Associated With Enhanced Viral Suppression. J Acquir Immune Defic Syndr. 2011;58(2):132–140.
[55]	Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol Baltim Md 1950. 1996 Apr 1;156(7):2616–2623.
[56]	Cellerai C, Harari A, Stauss H, Yerly S, Geretti A-M, Carroll A, et al. Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors. PLoS ONE. 2011 Apr 5;6(4):e18164.
[57]	Greenough TC, Brettler DB, Kirchhoff F, Alexander L, Desrosiers RC, O’Brien SJ, et al. Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort. J Infect Dis. 1999 Dec;180(6):1790–1802.
[58]	Ferrari G, Korber B, Goonetilleke N, Liu MKP, Turnbull EL, Salazar-Gonzalez JF, et al. Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathog. 2011;7(2):14.
[59]	Harari A, Pantaleo G. HIV‐1‐Specific Immune Response. Elsevier Inc; 2008.
[60]	Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis. 2010 Oct 15;202 Suppl 2:S302–308.
[61]	Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8 T cells. PLoS Med. 2008;5(5):e100.
[62]	Poles MA, Shady Barsoum, Wenjie Yu, Jian Yu, Sun P, Daly J, et al. Human Immunodeficiency Virus Type 1 Induces Persistent Changes in Mucosal and Blood __ T Cells despite Suppressive Therapy. Am Soc Microbiol. 2003 Oct;Vol. 77, No. 19:10456–10467.
[63]	Tenorio AR, Spritzler J, Martinson J, Gichinga CN, Pollard RB, Lederman MM, et al. The Effect of Aging on T-regulatory Cell Frequency in HIV Infection. Clin Immunol Orlando Fla. 2009 Mar;130(3):298–303.
[64]	Gaardbo JC, Nielsen SD, Vedel SJ, Ersbøll AK, Harritshøj L, Ryder LP, et al. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy. Clin Exp Immunol. 2008 Oct;154(1):80–86.
[65]	Lubaki NM, Shepherd ME, Brookmeyer RS, Hon H, Quinn TC, Kashamuka M, et al. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement. J Acquir Immune Defic Syndr 1999. 1999 Sep 1;22(1):19–30.
[66]	Santagostino A, Garbaccio G, Pistorio A, Bolis V, Camisasca G, Pagliaro P, et al. An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults. Haematologica. 1999 Jan 1;84(6):499–504.
[67]	Pattanapanyasat K. Immune status monitoring of HIV/AIDS patients in resource-limited settings: a review with an emphasis on CD4+ T-lymphocyte determination. Asian Pac J Allergy Immunol Launched Allergy Immunol Soc Thail. 2012 Mar;30(1):11–25.
[68]	Oxenius A, Price DA, Dawson SJ, Günthard HF, Fischer M, Perrin L, et al. Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load. AIDS Lond Engl. 2002 Nov 22;16(17):2317–2322.
[69]	Lambert C, Genin C. CD3 bright lymphocyte population reveal gammadelta T cells. Cytometry B Clin Cytom. 2004 Sep;61(1):45–53.
[70]	Sharp ER, Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, et al. Association of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected children. PloS One. 2012;7(1):e29154.
[71]	Pauza CD, Riedel DJ, Gilliam BL, Redfield RR. Targeting γδ T cells for immunotherapy of HIV disease. Future Virol. 2011 Jan;6(1):73–84.
[72]	Tenorio AR, Spritzler J, Martinson J, Gichinga CN, Pollard RB, Lederman MM, et al. The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol Orlando Fla. 2009 Mar;130(3):298–303.
[73]	Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R, et al. Naïve T-Cell Dynamics in Human Immunodeficiency Virus Type 1 Infection: Effects of Highly Active Antiretroviral Therapy Provide Insights into the Mechanisms of Naïve T-Cell Depletion. J Virol. 2006 Mar 15;80(6):2665–2674.
[74]	Cheng S, Wang Z, Wang L, Zhang M. [Ki-67 expression in stage III cervical squamous cell carcinoma and its correlation with sensitivity to chemoradiotherapy]. Zhonghua Zhong Liu Za Zhi. 2014 Sep;36(9):667–670.
[75]	Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000 Jan 1;95(1):249–255.
[76]	Hainaut M, Verscheure V, Ducarme M, Schandené L, Levy J, Mascart F. Cellular immune responses in human immunodeficiency virus (HIV)-1-infected children: is immune restoration by highly active anti-retroviral therapy comparable to non-progression? Clin Exp Immunol. 2011;165(1):77–84.
[77]	Tiba F, Nauwelaers F, Traoré S, Coulibaly B, Ouedraogo T, Compaoré A, et al. Immune Reconstitution During the First Year of Antiretroviral Therapy of HIV-1-Infected Adults in Rural Burkina Faso. Open AIDS J. 2012 Feb 24;6:16–25.
[78]	Lacabaratz-Porret C, Urrutia A, Doisne J-M, Goujard C, Deveau C, Dalod M, et al. Impact of Antiretroviral Therapy and Changes in Virus Load on Human Immunodeficiency Virus (HIV)–Specific T Cell Responses in Primary HIV Infection. J Infect Dis. 2003 Mar 1;187(5):748–757.
[79]	Keating SM, Golub ET, Nowicki M, Young M, Anastos K, Crystal H, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS Lond Engl. 2011 Sep 24;25(15):1823–1832.
[80]	Huruy K, Kassu A, Mulu A, Wondie Y. Immune restoration disease and changes in CD4+ T-cell count in HIV- infected patients during highly active antiretroviral therapy at Zewditu memorial hospital, Addis Ababa, Ethiopia. AIDS Res Ther. 2010 Dec 21;7:46.
[81]	Huruy K, Mulu A, Mengistu G, Shewa-Amare A, Akalu A, Kassu A, et al. Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia. Jpn J Infect Dis. 2008 May;61(3):205–209.
[82]	Crabtree-Ramírez B, Villasís-Keever A, Galindo-Fraga A, del Río C, Sierra-Madero J. Effectiveness of Highly Active Antiretroviral Therapy (HAART) Among HIV-Infected Patients in Mexico. AIDS Res Hum Retroviruses. 2010 Apr;26(4):373–378.
[83]	Knapp DJ, Brumme ZL, Huang SY, Wynhoven B, Dong WW, Mo T, Harrigan PR, Brumme CJ. Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1. Clin Infect Dis. 2012 Jun;54(11):1652-1659.
[84]	Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brenchley J, Fox C, et al. Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis. 2009 Jun 1;199(11):1648–1656.
[85]	Bisset LR, Cone RW, Huber W, Battegay M, Vernazza PL, Weber R, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS Lond Engl. 1998 Nov 12;12(16):2115–2123.
[86]	Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr. 1991;4(7):704–712.
[87]	Pontesilli O, Kerkhof-Garde S, Notermans DW, Foudraine NA, Roos MTL, Klein MR, et al. Functional T Cell Reconstitution and Human Immunodeficiency Virus—1—Specific Cell-Mediated Immunity during Highly Active Antiretroviral Therapy. J Infect Dis. 1999 Jul 1;180(1):76–86.
[88]	Kassu A, Tsegaye A, Petros B, Wolday D, Hailu E, Tilahun T, et al. Distribution of Lymphocyte Subsets in Healthy Human Immunodeficiency Virus-Negative Adult Ethiopians from Two Geographic Locales. Clin Vaccine Immunol. 2001 Nov 1;8(6):1171–1176.
[89]	Buseyne F, Chenadec JL, Corre B, Porrot F, Burgard M, Rouzioux C, et al. Inverse Correlation between Memory Gag-Specific Cytotoxic T Lymphocytes and Viral Replication in Human Immunodeficiency Virus–Infected Children. J Infect Dis. 2002 Dec 1;186(11):1589–1596.
[90]	Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med. 2007 Oct 1;204(10):2473–2485.
[91]	Montes M, Lewis DE, Sanchez C, Lopez de Castilla D, Graviss EA, Seas C, et al. Foxp3+ regulatory T cells in antiretroviral-naive HIV patients. AIDS Lond Engl. 2006 Aug 1;20(12):1669–1671.
[92]	Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008 Jul;8(7):523–532.
[93]	Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-κB to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5138–5143.
[94]	Paust S, Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev. 2005;204(1):195–207.
[95]	Jiao Y, Fu J, Xing S, Fu B, Zhang Z, Shi M, et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology. 2009 Sep;128(1 Suppl):e366–375.
[96]	Roncador G, Brown PJ, Maestre L, Hue S, Martínez-Torrecuadrada JL, Ling K-L, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol. 2005 Jun;35(6):1681–1691.
[97]	Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus–driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. 2004 Nov 15;104(10):3249–3256.
[98]	Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of Regulatory T Cells in HIV Infection Is Associated with Immune Activation. J Immunol. 2005 Apr 1;174(7):4407–4414.
[99]	Li D, Chen J, Jia M, Hong K, Ruan Y, Liang H, et al. Loss of balance between T helper type 17 and regulatory T cells in chronic human immunodeficiency virus infection. Clin Exp Immunol. 2011 Sep;165(3):363–371.
[100]	Goodkin K, Shapshak P, Asthana D, Zheng W, Concha M, Wilkie FL, et al. Older age and plasma viral load in HIV-1 infection. AIDS Lond Engl. 2004 Jan 1;18 Suppl 1:S87–98.
[101]	Freguja R, Gianesin K, Mosconi I, Zanchetta M, Carmona F, Rampon O, et al. Regulatory T cells and chronic immune activation in human immunodeficiency virus 1 (HIV-1)-infected children. Clin Exp Immunol. 2011 Jun;164(3):373–380.
[102]	Wallace M, Scharko AM, Pauza CD, Fisch P, Imaoka K, Kawabata S, et al. Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Mol Med. 1997 Jan;3(1):60–71.
[103]	Li H, Chaudry S, Poonia B, Shao Y, Pauza CD. Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications. Cell Mol Immunol. 2013 Jan;10(1):42–49.
[104]	Poccia F, Gougeon M-, Agrati C, Montesano C, Martini F, Pauza C, et al. Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes. Curr Mol Med. 2002 Dec 1;2(8):769–81.
[105]	Nilssen DE, Brandtzaeg P. Intraepithelial cd T Cells Remain Increased in the Duodenum of AIDS Patients Despite Antiretroviral Treatment. Open Access Line. 2012 Jan 4;7(1):1–8.
[106]	Ali Z, Yan L, Plagman N, Reichenberg A, Hintz M, Jomaa H, et al. Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits. J Immunol Baltim Md 1950. 2009 Oct 15;183(8):5407–5417.
[107]	Li Z, Li W, Li N, Jiao Y, Chen D, Cui L, Hu Y, Wu H, He W. γδ T cells are involved in acute HIV infection and associated with AIDS progression. PLoS One. 2014 Sep 4;9(9).
[108]	García VE, Sieling PA, Gong J, Barnes PF, Uyemura K, Tanaka Y, Bloom BR, Morita CT, Modlin RL. Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. J Immunol. 1997 Aug 1;159(3):1328-1335.
[109]	Martini F, Urso R, Gioia C, De Felici A, Narciso P, Amendola A, et al. γδ T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology. 2000; 100(4):481–486.
[110]	[110] Habtamu Wondiferaw Bayenes, Mehidi Kassim Ahmed, Tilahun Yemane Shenkute, Yaregal Asres Ayenew, Lealem Gedefaw Bimerew. Prevalence and Predictors of Dyslipidemia on HAART and HAART Naive HIV Positive Persons in Defense Hospital, Addis Ababa,Ethiopia. American Journal of Health Research. 2014;2(5):303-309.
[111]	[111] Kandi Venkataramana. A Study of Biological Markers in HIV Disease Progression and Management in yhe Highly Active Antiretroviral Therapy (HAART) Era. American Journal of Bioscience and Bioengineering. Vol. 1, No. 2, 2013;1(2): 24-37.

Cite This Article

Plain Text BibTeX RIS

APA Style

Addisu Gize Yeshanew, Afework Kassu Gizaw, Biniam Mathewos Tebeje. (2015). Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients. International Journal of Immunology, 3(6), 57-71. https://doi.org/10.11648/j.iji.20150306.11

Copy | Download

ACS Style

Addisu Gize Yeshanew; Afework Kassu Gizaw; Biniam Mathewos Tebeje. Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients. Int. J. Immunol. 2015, 3(6), 57-71. doi: 10.11648/j.iji.20150306.11

Copy | Download

AMA Style

Addisu Gize Yeshanew, Afework Kassu Gizaw, Biniam Mathewos Tebeje. Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients. Int J Immunol. 2015;3(6):57-71. doi: 10.11648/j.iji.20150306.11

Copy | Download

@article{10.11648/j.iji.20150306.11,
  author = {Addisu Gize Yeshanew and Afework Kassu Gizaw and Biniam Mathewos Tebeje},
  title = {Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients},
  journal = {International Journal of Immunology},
  volume = {3},
  number = {6},
  pages = {57-71},
  doi = {10.11648/j.iji.20150306.11},
  url = {https://doi.org/10.11648/j.iji.20150306.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20150306.11},
  abstract = {The range of T cell abnormalities in advanced HIV-1 infection treatment is broad. The defects are both quantitative and qualitative and affect virtually every limb of the immune system. Beyond the precise measurement of naive T cells (CD45RA+CCR7+CD27+CD28+), the differential expression of different molecules on T cell allows the distinction between numerous subsets of resting or antigen-experienced T cells on the treatment. However, in spite of intense investigation, the mechanisms underlying highly active antiretroviral therapy (HAART) –induce immune reconstitution remain to be fully characterized. HAART treatment induced changes in the peripheral distribution of naïve (CD45RA+ CD62L+) and memory CD45RA- CD62L+) cells, CCR5, CXCR4-, CD95- expressing T cells, T-reg cells and on gamma delta (ϒδ) T cells. As a concluding remark prolonged suppression of plasma viral load ( pVL) by HAART improves not only ɑβ T-cell function but also ϒδ T-cell reactivity, and it is strongly recommended that once started the treatment, sever immunocompromized patient should continue the treatment for long time.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients
AU  - Addisu Gize Yeshanew
AU  - Afework Kassu Gizaw
AU  - Biniam Mathewos Tebeje
Y1  - 2015/11/26
PY  - 2015
N1  - https://doi.org/10.11648/j.iji.20150306.11
DO  - 10.11648/j.iji.20150306.11
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 57
EP  - 71
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20150306.11
AB  - The range of T cell abnormalities in advanced HIV-1 infection treatment is broad. The defects are both quantitative and qualitative and affect virtually every limb of the immune system. Beyond the precise measurement of naive T cells (CD45RA+CCR7+CD27+CD28+), the differential expression of different molecules on T cell allows the distinction between numerous subsets of resting or antigen-experienced T cells on the treatment. However, in spite of intense investigation, the mechanisms underlying highly active antiretroviral therapy (HAART) –induce immune reconstitution remain to be fully characterized. HAART treatment induced changes in the peripheral distribution of naïve (CD45RA+ CD62L+) and memory CD45RA- CD62L+) cells, CCR5, CXCR4-, CD95- expressing T cells, T-reg cells and on gamma delta (ϒδ) T cells. As a concluding remark prolonged suppression of plasma viral load ( pVL) by HAART improves not only ɑβ T-cell function but also ϒδ T-cell reactivity, and it is strongly recommended that once started the treatment, sever immunocompromized patient should continue the treatment for long time.
VL  - 3
IS  - 6
ER  -

Copy | Download

Author Information

Addisu Gize Yeshanew

Department of Microbiology, Immunology and Parasitology, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia
Afework Kassu Gizaw

Department of Microbiology, Immunology and Parasitology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
Biniam Mathewos Tebeje

QIMR Berghofer Medical Research Institute, Brisbane, Australia; School of Public Health, University of Queensland, Brisbane, Australia; Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Addisu Gize Yeshanew, Afework Kassu Gizaw, Biniam Mathewos Tebeje. (2015). Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients. International Journal of Immunology, 3(6), 57-71. https://doi.org/10.11648/j.iji.20150306.11

Copy | Download

ACS Style

Addisu Gize Yeshanew; Afework Kassu Gizaw; Biniam Mathewos Tebeje. Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients. Int. J. Immunol. 2015, 3(6), 57-71. doi: 10.11648/j.iji.20150306.11

Copy | Download

AMA Style

Addisu Gize Yeshanew, Afework Kassu Gizaw, Biniam Mathewos Tebeje. Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients. Int J Immunol. 2015;3(6):57-71. doi: 10.11648/j.iji.20150306.11

Copy | Download

@article{10.11648/j.iji.20150306.11,
  author = {Addisu Gize Yeshanew and Afework Kassu Gizaw and Biniam Mathewos Tebeje},
  title = {Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients},
  journal = {International Journal of Immunology},
  volume = {3},
  number = {6},
  pages = {57-71},
  doi = {10.11648/j.iji.20150306.11},
  url = {https://doi.org/10.11648/j.iji.20150306.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20150306.11},
  abstract = {The range of T cell abnormalities in advanced HIV-1 infection treatment is broad. The defects are both quantitative and qualitative and affect virtually every limb of the immune system. Beyond the precise measurement of naive T cells (CD45RA+CCR7+CD27+CD28+), the differential expression of different molecules on T cell allows the distinction between numerous subsets of resting or antigen-experienced T cells on the treatment. However, in spite of intense investigation, the mechanisms underlying highly active antiretroviral therapy (HAART) –induce immune reconstitution remain to be fully characterized. HAART treatment induced changes in the peripheral distribution of naïve (CD45RA+ CD62L+) and memory CD45RA- CD62L+) cells, CCR5, CXCR4-, CD95- expressing T cells, T-reg cells and on gamma delta (ϒδ) T cells. As a concluding remark prolonged suppression of plasma viral load ( pVL) by HAART improves not only ɑβ T-cell function but also ϒδ T-cell reactivity, and it is strongly recommended that once started the treatment, sever immunocompromized patient should continue the treatment for long time.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Effect of Highly Active Antiretroviral Therapy on T-Cell Sub-population Profile in Human Immunodeficiency Virus-1 Infected Patients
AU  - Addisu Gize Yeshanew
AU  - Afework Kassu Gizaw
AU  - Biniam Mathewos Tebeje
Y1  - 2015/11/26
PY  - 2015
N1  - https://doi.org/10.11648/j.iji.20150306.11
DO  - 10.11648/j.iji.20150306.11
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 57
EP  - 71
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20150306.11
AB  - The range of T cell abnormalities in advanced HIV-1 infection treatment is broad. The defects are both quantitative and qualitative and affect virtually every limb of the immune system. Beyond the precise measurement of naive T cells (CD45RA+CCR7+CD27+CD28+), the differential expression of different molecules on T cell allows the distinction between numerous subsets of resting or antigen-experienced T cells on the treatment. However, in spite of intense investigation, the mechanisms underlying highly active antiretroviral therapy (HAART) –induce immune reconstitution remain to be fully characterized. HAART treatment induced changes in the peripheral distribution of naïve (CD45RA+ CD62L+) and memory CD45RA- CD62L+) cells, CCR5, CXCR4-, CD95- expressing T cells, T-reg cells and on gamma delta (ϒδ) T cells. As a concluding remark prolonged suppression of plasma viral load ( pVL) by HAART improves not only ɑβ T-cell function but also ϒδ T-cell reactivity, and it is strongly recommended that once started the treatment, sever immunocompromized patient should continue the treatment for long time.
VL  - 3
IS  - 6
ER  -

Copy | Download